From tumor immunity to precision medicine: the next step in B7-H3/CD276 research

B7-H3 (CD276) is one of the immune checkpoint molecules at the forefront of cancer biology, plays a diverse role in immune regulation and cancer progression, while its immunosuppressive functions enable tumors to escape immune detection, its contribution to processes such as angiogenesis, metabolic reprogramming and chemoresistance underscores its broader impact on the tumor microenvironment (TME). These properties make B7-H3 an attractive target for cancer therapy. This perspective discusses the immune and non-immune related functions of B7-H3, the challenges in tapping its therapeutic potential.